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Abstract
Background and aim
Circulating fibroblast activation protein (cFAP) is a constitutively active enzyme expressed
by activated fibroblasts that has both dipeptidyl peptidase and endopeptidase activities. We
aimed to assess the correlation between cFAP activity and antigen levels and to compare
variations in levels.
Methods
In plasma of 465 control individuals, 368 patients with coronary heart disease (CHD) and
102 hepatitis C virus (HCV) infected patients with severe liver disease before and after liver
transplant, cFAP activity levels were measured with a newly developed cFAP activity assay.
In the same samples, cFAP antigen levels were measured using a commercially available
cFAP ELISA. Correlation analyses between activity and antigen levels were performed by
calculating Pearson’s correlation coefficient (ρ). Additionally, normal ranges, determinants
and differences between cohorts and between anticoagulants were investigated.
Results
cFAP activity and antigen levels significantly correlated in controls (ρ: 0.660, p<0.001) and
in CHD patients (ρ: 0.709, p<0.001). cFAP activity and antigen levels in the HCV cohort
were significantly lower in the samples taken after liver transplantation (p<0.001) and nor-
malized toward levels of healthy individuals. Furthermore, cFAP activity and antigen levels
were higher in men and significantly associated with body mass index. Also, cFAP activity
and antigen levels were higher in EDTA plasma as compared to the levels in citrated plasma
from the same healthy individuals.
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Conclusions
For analyzing cFAP levels, either activity levels or antigen levels can be measured to investi-
gate differences between individuals. However, it is of importance that blood samples are
collected in the same anticoagulant.
Introduction
The serine protease fibroblast activation protein (FAP) is a member of the dipeptidyl peptidase
(DPP) 4 family [1]. FAP is a constitutively active enzyme that has both DPP and endopeptidase
activities and is expressed in tissues by activated fibroblasts. A derivative of FAP circulates in
the blood (cFAP). Substrates of FAP include collagen type I [2, 3], fibroblast growth factor-21
[4], alpha-2-antiplasmin (α2AP) [5] and the neuropeptides B-type natriuretic peptide, neuro-
peptide Y, substance P and peptide YY [6, 7].
We recently developed a robust and sensitive assay to quantify cFAP activity in organs and
fluids using the FAP-specific substrate 3144-amino methyl-coumarin (AMC) [8]. We showed
that FAP is a highly promising biomarker, as both tissue and circulating levels are low in
healthy individuals, but FAP is elevated in diseased organs and cFAP is elevated in cirrhosis [8,
9]. Similarly, elevated cFAP was restricted to subjects with moderate to severe fibrosis in
patients with type 2 diabetes or undergoing bariatric surgery [9, 10]. Significantly, low cFAP
values had a negative predictive value for gradeF2 fibrosis of 95% and cFAP activity mea-
surement was used to re-classify more than 40% patients who had been classified as ‘indeter-
minate risk’ by the non-alcoholic fatty liver disease fibrosis score algorithm as ‘low risk of
fibrosis’ [10]. These data indicate that cFAP can have clinical utility for increasing the precision
of assessing which patients are at risk of fibrosis and thus require transient elastography. To
further establish cFAP as a diagnostic biomarker for current and perhaps regressing liver fibro-
sis more investigation is needed.
In two other studies, we used a commercially available cFAP ELISA and showed increased
cFAP antigen levels in liver disease [11] and equal cFAP antigen levels in patients with a recent
arterial thrombotic event, including acute myocardial infarction and ischemic stroke [12]. The
present study aimed to assess the correlation between our new cFAP activity assay that specifi-
cally measures cFAP enzyme activity and the commercial cFAP antigen assay that is specific
for cFAP protein levels. We additionally investigated determinants of cFAP activity in healthy
control individuals and examined differences in cFAP levels between individuals. For this we
used the plasma samples of 3 different cohorts: 1] a control cohort consisting of healthy indi-
viduals, 2] a cohort of patients with coronary heart disease (CHD), containing patients with
acute myocardial infarction or unstable angina pectoris, and 3] a cohort of hepatitis C virus
(HCV) infected patients with severe liver disease of whom blood was taken before and/or after
a liver transplant. The results show a strong correlation between the activity levels and the anti-
gen levels of cFAP.
Materials and methods
Plasma samples
The control cohort and the CHD cohort derived from the ‘Genetic risk factors for Arterial
Thrombosis at young age: the role of TAFI and other Coagulation factors’ (ATTAC) study,
which has been described previously [13]. In short, 391 consecutive patients who presented
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with a first arterial thrombotic event at young age (males: 45 years or younger, females: 55
years or younger) were included. Control subjects (n = 465) had no history of cardiovascular
disease. Blood samples were collected in both 0.1 volume of sodium citrate (0.105 mol/L) and
in EDTA (final concentration: 6.16 mmol/L). The HCV cohort samples consisted of 142
plasma samples anticoagulated with EDTA (final concentration: 6.16 mmol/L) from 93
patients with Child-Pugh C cirrhosis pre-transplant (S1 Table). From 33 HCV patients, two or
more samples were obtained at different time points. For direct comparison, both citrate and
EDTA anticoagulated blood samples were additionally collected from 21 Australian healthy
individuals. All subjects provided written informed consent prior to undertaking any study
procedures. All procedures were approved by the Medical Ethics Committee of Erasmus MC
and the Sydney Local Health District Human Research Ethics Committee and were in accor-
dance with the Helsinki Declaration.
cFAP activity assay
Circulating FAP activity levels were measured using a recently developed in-house enzyme-
activity assay as described and validated [8]. Fluorescent standards in a linear range of 0–600
pmol AMC were used to interpolate cFAP activity in a 100-fold diluted plasma sample using
the FAP-specific substrate 3144-AMC at 150 μM. Inter- and intra-assay variation was 10.7%
and 4.5%, respectively. The activity of cFAP was converted to ng mL-1 with a standard curve of
recombinant human FAP (R&D Systems, Abingdon, UK) ranging from 0–400 ng mL-1 diluted
in PBS.
cFAP antigen assay
Circulating FAP antigen levels were measured using the human FAP DuoSet1 ELISA Devel-
opment kit (R&D Systems, Abingdon, UK), according to the manufacturer’s protocol, as
described [12, 14]. The cFAP level of a 200-fold diluted plasma sample was measured in dupli-
cate and was calculated as the mean result of the two measurements. The assay was calibrated
using recombinant human FAP (R&D Systems, Abingdon, UK) as standard. Inter- and intra-
assay variation was 12.5% and 3.5%, respectively.
Statistical analyses
Distributions of the cFAP activity and cFAP antigen levels in the cohorts were tested for nor-
mality using the Kolmogorov-Smirnov test. Natural log transformation was required to obtain
normal distributions. Data are presented as geometric mean and geometric standard deviation
(SD). Significance of correlation between cFAP activity and antigen levels were investigated
using Pearson’s correlation coefficient (ρ). In the control cohort, normal ranges for cFAP
activity and antigen levels were calculated as geometric mean ± 2 geometric SD (i.e. 95% confi-
dence interval). Differences in cFAP levels between cohorts or between different anticoagu-
lants (citrate and EDTA) were tested for significance using (paired) Student’s t-test on the log-
transformed data. Adjustments for confounders were made using linear regression. P-values
<0.05 were considered statistically significant. All statistical analyses were carried out using
SPSS software version 21.
Results
Sample characteristics
The baseline characteristics of the control individuals and CHD cohort have been published
previously [12]. In general, the control individuals were slightly younger (39 years, range: 18–
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57) than the CHD patients (44 years, range: 23–55). The control cohort contained 63.5%
females while the CHD cohort contained 44.0% females. The individuals of the HCV cohort
were older (57 years, range: 31–77) and predominantly male (15.8% females).
Correlation analyses
The scatterplot (Fig 1) illustrates the significant correlation between cFAP activity and antigen
levels. Similar correlation coefficients were found for the separate cohorts; ρ: 0.660, p<0.001 in
the control cohort and ρ: 0.709, p<0.001 in the CHD cohort, indicating that the correlation
between the assays is not influenced by CHD.
To compare cFAP antigen and activity levels in similar units, cFAP activity levels were con-
verted from pmol AMC min-1 mL-1 to ng mL-1. On average, cFAP antigen levels were 4.7-fold
higher than the cFAP activity levels in ng mL-1.
Normal ranges
As we have measured both cFAP activity and cFAP antigen levels in a large cohort of 465
healthy control individuals, we calculated normal ranges based on the 95% confidence interval
of the values in this cohort. We defined the normal range of cFAP activity to be 316–1360
pmol AMC/min/ml. The cFAP antigen normal range was defined as 49–159 ng/ml.
Fig 1. Correlation between sFAP activity levels and cFAP antigen levels. Control cohort (n = 465): open circles
and dashed line (r2 = 0.435). CHD cohort (n = 368): closed squares and solid line (r2 = 0.503). The axes are on a log
scale.
https://doi.org/10.1371/journal.pone.0178987.g001
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Determinants of cFAP activity level
In the control cohort we additionally investigated determinants of cFAP activity, as previously
performed for cFAP antigen levels [12]. As expected due to the strong correlation between the
assays, the determinants of cFAP activity were similar to the determinants of cFAP antigen lev-
els. Men had significantly higher cFAP activity levels than women (Table 1). Furthermore,
there was a significant positive association between body mass index (BMI) and cFAP activity
level, Spearman’s rho: 0.168, p<0.001.
Differences in cFAP activity levels between cohorts
We compared the levels between the different cohorts and found that the cFAP activity levels
in the control cohort were similar to those in the CHD cohort, p = 0.561 after adjustment for
age and gender (Table 1). Additional adjustment for BMI did not change this, p = 0.800. These
results are in line with our previous study in which we showed no differences in cFAP antigen
levels between healthy individuals and CHD patients [12].
In the HCV cohort (S1 Table) we compared samples taken before liver transplantation
(n = 32) with samples taken after liver transplantation (n = 110). To allow clearance of the pre-
transplant cFAP and for immunosuppressive treatment to stabilize, samples taken up to 6
months after liver transplantation were excluded. Both cFAP activity levels and cFAP antigen
levels were significantly lower in the samples taken after liver transplantation, p<0.001 after
adjustment for age and gender (Table 1) and normalized toward the levels found in the plasma
of control individuals.
Differences in cFAP levels between anticoagulants
cFAP levels of the control and CHD cohorts were measured in citrated plasma, whereas the
cFAP levels of the HCV cohort were measured in EDTA plasma. Therefore, we additionally
tested whether cFAP levels differed between the two anticoagulants. We found that cFAP lev-
els, activity as well as antigen, were significantly greater in EDTA plasma compared to citrated
plasma (Table 1).
Table 1. cFAP activity and antigen levels in the different cohorts.
Cohort cFAP activity (pmol AMC min-1 mL-1) P-value† cFAP antigen (ng mL-1) P-value‡
Male controls§ (n = 166) 704 ± 273 <0.001 95 ± 29 <0.001[12]
Female controls§ (n = 299) 627 ± 224 84 ± 24
Control cohort§ (n = 465) 656 ± 244 0.561 88 ± 26 0.849[12]
CHD cohort§ (n = 368) 696 ± 272 89 ± 29
HCV cohort¶ (pre-Tx, n = 32) 1625 ± 613 <0.001 146 ± 49 <0.001
HCV cohort¶ (post-Tx, n = 110) 1055 ± 463 103 ± 45
EDTA plasma (n = 21†; n = 25‡) 1087 ± 287 <0.001 129 ± 42 0.001
Citrate plasma (n = 21†; n = 25‡) 893 ± 214 113 ± 43
P-values are adjusted for age and gender. cFAP: circulating fibroblast activation protein; Tx: transplant;
†cFAP activity;
‡cFAP antigen;
§citrated plasma;
¶EDTA plasma.
https://doi.org/10.1371/journal.pone.0178987.t001
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Discussion
In this study we showed that cFAP antigen levels (detected by ELISA) correlate strongly with
cFAP enzyme activity (detected by synthetic fluorescence substrate assay). This suggests that
the proportion of cFAP protein measured by this ELISA is enzymatically active and stable. The
data imply that there are no endogenous inhibitors of cFAP and that cFAP stability is not
affected by major influences such as the presence of cirrhosis or immunosuppression.
Conversion of the activity data into ng mL-1 showed that on average the antigen levels were
4.7-fold higher than the activity levels. This may be explained by the fact that only fully intact
cFAP homodimers have activity [15], whereas the ELISA will measure various forms of cFAP.
In plasma some of the FAP will be monomeric or fragments that can be detected by the ELISA
but will not be measured by our activity assay. However, we showed that both assays are reli-
able for detecting differences between individuals and cohorts. The data presented in this
study is pertinent only to the specific antibodies used in the ELISA employed here. Other anti-
bodies may give different results.
We previously showed that, with adjustment for age and gender, cFAP is not significantly
different in CHD patients and in control individuals [12], and this finding is now indepen-
dently confirmed using the FAP activity assay. In addition, we recently showed that neither
rheumatoid arthritis nor systemic sclerosis alter cFAP activity levels [9]. Interestingly, the pres-
ent study showed for the first time that cFAP levels decrease following the establishment of a
healthy transplanted donor liver that replaced a cirrhotic liver. Our recent data indicates that
lacking FAP does not alter immunity to influenza in mice [16]. However, FAP-expressing cells
have been associated with impaired immunity in mice [17], so cFAP might potentially be influ-
enced by the immunosuppression that is administered post-transplant. Therefore, we exam-
ined cFAP only 6 months or more post-transplant. As there were only three individuals from
whom we had a plasma sample obtained both before and after liver transplantation, we could
not perform paired analyses. Nevertheless, the observation that after liver transplantation
cFAP levels normalized toward levels of healthy individuals supports growing evidence that
activated stellate cells and activated myofibroblasts in the liver, which are prevalent in cirrho-
sis, are major sources of cFAP above the levels found in healthy individuals [18, 19]. Our previ-
ous work showed that cFAP in liver cirrhosis patients is elevated, with highest levels when
fibrosis is worst (Child-Pugh C) [8, 11], and that low cFAP has a 95% negative predictive value
forF2 fibrosis [10]. Thus, cFAP may have clinical utility as a biomarker for progression and
regression of liver fibrosis.
The cFAP activity levels positively associated with male gender and with BMI. Both obser-
vations might relate to hormonal influence, and an analysis of the FAP gene promotor sup-
ports this concept [20]. FAP can inactivate the starvation hormone FGF21 in humans, and
FAP deficient mice and FAP-inhibited mice are leaner than controls (Gorrell MD, unpub-
lished results) [21], so elevated cFAP might associate with BMI due to a metabolic function of
FAP such as FGF21 inactivation.
Furthermore, we found higher cFAP activity and antigen levels in EDTA plasma as com-
pared to the levels in citrated plasma from the same healthy individuals, suggesting that the
anticoagulant may interfere with the cFAP level. However, as the 0.1 volume of citrate can
dilute the plasma up to 18% (assuming an average hematocrit of 45%) this may explain the
higher values found in undiluted EDTA plasma. Accordingly, the cFAP activity levels in undi-
luted EDTA plasma and serum do not differ [8]. The results of our studies are not influenced
by this dilution, as the same anticoagulants were used within the cohorts. Furthermore, the lev-
els of the patients of the pre-transplant HCV cohort are higher than can be explained by the
anticoagulant dilution only.
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In summary, we show that for analyzing cFAP levels, either activity levels or antigen levels
can be measured and that it is of importance that blood samples are collected in the same
anticoagulant.
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